Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kneat.com Inc T.KSI

Alternate Symbol(s):  KSIOF

kneat.com, inc. develops and markets the Kneat Gx software-as-a-service (SaaS) platform. It designs, develops and supplies software for data and document management within regulated environments. The Company’s focus is to service the facilities, equipment and computer systems (CSV) validation market initially within the global life sciences industry. The Company’s product is Kneat Gx, a configurable, off-the-shelf application focused on validation lifecycle management and testing primarily within the life sciences industry. Kneat Gx provides a compliant digital solution that enables companies in the life sciences industry to become efficient and compliant with an automated process that has traditionally been manual, inefficient and paper-based. Its various validation processes include electronic logbook management, analytical instrument validation, utility and facility validation, process validation, method validation and equipment validation, cold chain validation, and others.


TSX:KSI - Post by User

Post by Possibleidiot01on Apr 14, 2023 3:35pm
157 Views
Post# 35395870

Michael Hakes - BNN- Past Top Pick

Michael Hakes - BNN- Past Top Pick
PAST TOP PICK
(A Top Pick Aug 22/22, Down 17%)

Software company that is based in Ireland. 
Offers compliance and validation software in life sciences business.
Currently has 8/10 of top pharma & 18/20 top bio-pharma companies as customers. 
Growing customer base at a rapid rate.
Very positive on outlook of business.
Will continue to own shares.

 

Technology
<< Previous
Bullboard Posts
Next >>